趋化因子CXCL14在鼻咽癌组织中的表达及其临床意义

摘要
图/表
参考文献
相关文章 (7)

全文: PDF (1652 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：分析趋化因子CXCL14在鼻咽癌组织中的表达，并探讨其临床意义。方法：采集30例鼻咽癌患者（鼻咽癌组）及30例鼻咽炎患者（正常对照组）鼻咽部组织，采用实时荧光定量PCR和免疫组织化学方法进行CXCL14表达的检测。结果：CXCL14 mRNA和蛋白水平在鼻咽癌组的表达较正常对照组明显降低，差异有统计学意义（P＜0.001）。临床相关性分析表明，CXCL14表达的下调与肿瘤T分级（P=0.001）、淋巴结转移（P=0.028）及临床分期（P=0.001）相关。结论：鼻咽癌组织中CXCL14 mRNA和蛋白水平表达下降，CXCL14可能参与鼻咽癌的发生、发展过程。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周益飞1
	王照亮1
	张瑜1
	陈琴1
	郑翔2
	佟笑1
	3
	黄益灯1
	3

关键词 ：趋化因子CXCL14, 鼻咽肿瘤, 鼻咽炎, 免疫组织化学

Abstract：Objective: To investigate the expression of chemokine CXCLl4 and its clinical significance in nasopharyngeal cancer (NPC). Methods: Thirty patients with NPC were selected as the disease group and another 30 cases with nasopharyngitis as control group. Biopsy with nasopharyngeal tissue was performed. The CXCLl4 expression was detected with real-time fluorescence quantitative PCR and immunohistochemistry. Results: The CXCLl4 expression with NPC tissues in mRNA and protein levels declined compared with the control group (P<0.001). Correlative analysis showed the dow-nregulation of CXCLl4 expression in protein levels with NPC tissues was associated with T classification of tumor (P=0.001), lymph node metastasis (P=0.028) and the clinical stage (P=0.001). Conclusion: It is possible that CXCLl4 plays a role in the development and progression of NPC.

Key words： chemokine CXCLl4 nasopharyngeal neoplasm nasopharyngitis immunohistochemistry

收稿日期: 2015-08-09

通讯作者: 黄益灯，主任医师，硕士生导师，Email：huang_yi-deng@126.com。

作者简介: 周益飞（1975-），男，浙江温州人，主治医师，在职硕士生。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2015/V45/I11/814

[1] 徐国镇, 唐平章, 罗京伟. 加强以放射治疗为主的鼻咽癌综合治疗研究[J]. 中华耳鼻咽喉头颈外科杂志, 2012, 47 (3): 177-179.
[2] 朱鲁程, 邹长林. EGFR单抗联合放疗与单纯放疗在中晚期鼻咽癌中疗效比较的Meta分析[J]. 温州医学院学报,2013, 43(9): 626-629.
[3] Hara T, Tanegashima K. Pleiotropic functions of the CXCtype chemokine CXCL14 in mammals [J]. Biochem, 2012,151(5): 469-476.
[4] Wong MM, Fish EN. Chemokines: attractive mediators of the immune response[J]. Semin Immunol, 2003, 15(1): 5-14.
[5] Hromas R, Broxmeyer HE, Kim C, et a1. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells[J]. Bioehem Biophys Res Commun, 1999, 255(3): 703-706.
[6] Tanegashima K, Suzuki K, Nakayama Y, et al. CXCL14 is anatural inhibitor of the CXCL12-CXCR4 signaling axis[J]. FEBS Lett, 2013, 587(12): 1731-1735.
[7] Frederick MJ, Henderson Y, Xu X, et a1. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue[J]. Am J Pathol, 2000, 156(6): 1937-1950.
[8] Kuang H, Chen Q, Fan X, et al. CXCL14 inhibits trophoblast outgrowthvia a paracrine autocrine manner during early pregnancy in mice[J]. J Cell Physiol, 2009, 221(2): 448-457.
[9] Wikman H, Westphal L, Schmid F, et al. Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients[J]. Oncotarget, 2014, 5(10): 3076-3087.
[10] Hu C, Lin F, Zhu G, et a1. Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancer[J]. Int J Oncol, 2013, 43(5): 1487-1494.
[11] Song EY, Shurin MR, Tourkova IL, et al. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells[J]. Cancer Res, 2010, 70(11): 4394-4401.
[12] Cao B, Yang Y, Pan Y, et a1. Epigenetie silencing of CXCLl4 inducedeolorectal cancer migration and invasion[J]. Discov Med, 2013, 16(88): 137-147.
[13] Zeng J, Yang X, Cheng L, et a1. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection[J]. J Transl Med, 2013, 11(1):6-21.
[14] Lin K, Zou R, Lin F, et a1. Expression and effect of CXCL14 in colorectal carcinoma[J]. Mol Med Rep, 2014, 10(3): 1561-1568.
[15] Ozawa S, Kato Y, Komori R, et al. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells[J]. Biochem Biophys Res Commun, 2006, 348(2):406-412
[16] Ito S, Ozawa S, Ikoma T, et al. Expresssion of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vito[J]. Biomed Res, 2010, 31(3): 199-206.
[17] Ozawa S, Kato Y, Kubota E, et al. BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse[J]. Biomed Res, 2009, 30(5):315-318.
[18] Miyamoto C, Maehata Y, Motohashi K, et al. Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma[J]. Biomed Res, 2014, 35(6): 381-388.